Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

NCT07497399 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether a medication that activates the GLP-1 receptor can slow brain volume loss in adults with multiple sclerosis.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 120 people Planned (estimated).

Who can join Ages 18–60 · all sexes

Timeline Started 2026-04 · est. completion 2030-01

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07497399 ↗

Description as written by the study sponsor.

The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal volume (nBPV), measured by magnetic resonance imaging (MRI). Researchers will compare outcomes from participants randomized to the study drug, versus participants randomized to placebo, to see if there are signs of slowed neurodegeneration (i.e., reduction in brain and retinal atrophy).

Treatments tested

NLY01 Drug

NLY01 is a pegylated exenatide
Placebo Drug

Placebo (saline solution)

Main thing measured	Change in normalized (for head size) brain parenchymal volume (nBPV)
Sponsor	Johns Hopkins University
Conditions studied	Multiple Sclerosis
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07497399 ↗